Clinical decision support
Also, a Māori public health organisation develops a new tool to bring timely COVID-19-related information to Māori people.
The software automatically analyses chest CT images for pneumonia.
IntelliSite is designed to streamline workflows, enhance diagnostic confidence, facilitate collaboration, integrate AI and increase the efficiency of pathology labs.
Also, US-based Pearl has received regulatory approvals to market its AI diagnostic tool for dental radiology in Australia and New Zealand.
A new AI screening tool has been trained to identify 14 of the most common retinal abnormalities.
The SoftVue system is intended to be used in addition to digital mammograms to screen for cancer among patients with dense breast tissue.
Clinical research is set to verify the technology's effectiveness in estimating abnormal heart movements.
The latest approval marks DreaMed’s fourth clearance from the Food and Drug Administration.
It has a dashboard that renders an analysis of patient visit trends and actionable intelligence for clinic upgrades.
The tool is also able to check the lung condition of COVID-19 patients.